Major depressive disorder (MDD) is a chronic mental health condition that affects millions worldwide. For many individuals with MDD, the risk of suicidal ideation is high, especially when traditional antidepressants fail to provide relief. Over the past two decades, ketamine—a fast-acting anesthetic—has gained attention as a promising treatment option for those experiencing suicidal thoughts. While the short-term benefits of ketamine are well-known, its long-term effects have been less understood. A 2024 study published in Translational Psychiatry sheds new light on ketamine’s sustained ability to reduce suicidal ideation over time.
In this large-scale study, researchers led by Yiheng Pan analyzed electronic health records from over 500,000 patients diagnosed with recurrent MDD. The study compared outcomes between those prescribed ketamine and those treated with more traditional antidepressants, such as SSRIs and SNRIs.
Over a 270-day period, the study showed that patients prescribed ketamine experienced a significantly lower risk of suicidal ideation compared to those on standard antidepressants. This reduced risk was particularly strong in adults over 24 years of age, and was consistent across both male and female patients, regardless of race.
For individuals suffering from recurrent MDD, these findings offer renewed hope. Traditional antidepressants can take weeks to show effects, and many patients experience only partial relief. In contrast, ketamine has been shown to provide rapid antidepressant effects, and this study confirms that these benefits can last for several months or longer. The significant reduction in suicidal ideation suggests that ketamine may be an effective long-term solution for individuals at high risk of suicide.
Suicide remains a leading cause of death for individuals with MDD, especially in younger populations. While traditional antidepressants can help reduce the risk of suicide, their delayed onset of action is a major drawback. Ketamine, on the other hand, has been proven to reduce suicidal thoughts within hours, and this study confirms that these effects can persist for up to nine months.
For patients who have experienced multiple depressive episodes and are at heightened risk for suicide, ketamine offers a promising therapeutic option that may help disrupt the cycle of recurrent depression and reduce the risk of self-harm.
While this study highlights the long-term benefits of ketamine in reducing suicidal ideation, further research is needed to optimize its use in clinical practice. The study’s authors emphasize the need to explore ideal dosing regimens and to better understand how ketamine interacts with factors like age, gender, and race.
Ketamine is not without risks, especially when used in an unsupervised at-home setting. Potential side effects, including nausea, hypertension, and tolerance, need to be carefully managed. Combining ketamine therapy with psychotherapy, particularly ketamine-assisted psychotherapy, may enhance its effects and provide more comprehensive mental health care for patients.
The results of this large-scale study provide compelling evidence that ketamine is more than just a short-term fix for MDD. For patients with recurrent MDD, especially those at risk of suicide, ketamine can offer lasting relief from suicidal thoughts, significantly lowering their risk for up to nine months.
As more research is conducted, ketamine therapy is likely to become an increasingly important tool in mental health treatment, offering hope to those who have struggled to find lasting relief from depression and suicidal ideation.
About the Author
Dr. Ray Rivas, a former general and trauma surgeon with over a decade of experience utilizing ketamine, became a ketamine therapy specialist to treat mental health and pain after witnessing its profound impact on his hospital trauma patients and his own mental health. As the founder and medical director of Innerbloom Ketamine Therapy in San Luis Obispo, California, Dr. Rivas applies his extensive medical expertise to provide safe, evidence-based ketamine treatments for mood disorders, including depression, anxiety, PTSD, and chronic pain. His passion lies in helping patients find relief and rediscover hope through personalized, compassionate care.
Disclaimer: All content on this website, including (but not limited to) this statement, news, blog post, article, testimonial, or FAQ is not medical advice and should not be considered as such. This website cannot diagnose or treat any medical condition. Only a licensed medical professional who is familiar with you and your medical history can do that. Therefore, we cannot be responsible or liable for any actions taken by those who access our website or rely on its content. Please refer to the Terms & Conditions for more information.